Dermfree Wart Corn Remover

Description

This product is identified by the code 51945-4 and is associated with the principal display panel. The effective date for this labeling is December 16, 2024. The product is represented visually in an image file labeled "Label.jpg," which is in JPEG format. The display panel includes a multimedia reference that provides additional visual information regarding the product.

Uses and Indications

This drug is indicated for the removal of warts and corns.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. An optional step includes soaking the wart in warm water for approximately 5 minutes to enhance the effectiveness of the application. After washing, the area must be dried completely.

If necessary, the medicated plaster can be cut to appropriately fit the size of the wart. The plaster should then be applied directly to the wart. This application should be repeated every 48 hours as needed, with a maximum treatment duration of up to 12 weeks.

Contraindications

Use of this product is contraindicated in the following situations:

Application on irritated, infected, or reddened skin is prohibited due to the potential for exacerbating these conditions. The product should not be applied to genital warts, facial warts, moles, birthmarks, or warts with hair growing from them, as these areas may be sensitive and could lead to adverse reactions. Additionally, application on mucous membranes is contraindicated to prevent irritation and potential complications.

Contact with the eyes or face should be strictly avoided. In the event of accidental exposure to the eyes, it is essential to rinse thoroughly with water to mitigate any potential harm.

Warnings and Precautions

For external use only. This product is not intended for ingestion.

In the event of accidental ingestion, it is imperative to seek medical assistance immediately or contact a Poison Control Center.

Healthcare professionals should advise patients to discontinue use and consult their physician if discomfort persists. Prompt medical evaluation is essential to address any ongoing symptoms.

In cases of ingestion, emergency medical help should be sought without delay, reinforcing the importance of immediate action in such situations.

Side Effects

For external use only. Patients should discontinue use if discomfort persists. It is advised that individuals with diabetes or poor blood circulation consult a doctor prior to use.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Dermfree Wart Corn Remover (salicylic acid 40% wart corn remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be monitored closely, as the product must be kept out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or a Poison Control Center should be contacted without delay.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

There is no specific information available regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions that should be taken. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients and weigh the potential risks and benefits. Women of childbearing potential should be counseled on the absence of established safety data in pregnancy.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or its effects on lactation. Additionally, there are no data on the excretion of this medication in human breast milk or its potential effects on breastfed infants. Healthcare professionals should consider the lack of information when advising lactating mothers about the use of this medication.

Renal Impairment

Dosage adjustments may be necessary for patients with reduced renal function. Regular monitoring of renal function tests is recommended for patients with known kidney problems. A reduced dose should be considered for patients with a creatinine clearance of less than 30 mL/min. Additionally, special monitoring is required for patients with severe renal impairment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Furthermore, specific antidotes or treatments may be indicated based on the substance involved in the overdose. Consultation with a poison control center or a medical toxicologist is recommended to guide the management of the patient effectively.

Overall, vigilance and prompt intervention are critical in managing cases of suspected overdose, even in the absence of detailed information regarding specific overdosage effects.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question. Further studies may be necessary to elucidate these aspects of nonclinical toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to inform patients that the product should not be applied to irritated, infected, or reddened skin, as well as to genital warts, warts on the face, moles, birthmarks, or warts with hair growing from them, and mucous membranes.

Patients should be counseled to discontinue use and consult a healthcare professional if discomfort persists. Additionally, providers should emphasize the importance of avoiding contact with the eyes or face. In the event that the product comes into contact with the eyes, patients should be instructed to rinse thoroughly with water.

Healthcare providers should also recommend that patients consult a doctor if they have diabetes or poor blood circulation, as these conditions may affect the use of the product.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product within a temperature range of 59°F to 86°F (15°C to 30°C) to maintain its efficacy and integrity. Proper storage conditions must be adhered to, ensuring that the product is kept in a suitable container that protects it from environmental factors. Special handling requirements should be observed to prevent any compromise to the product's quality.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Dermfree Wart Corn Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)